

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Mannitol dry powder for inhalation for the treatment of cystic fibrosis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

During the scoping phase, the issue of the manipulation of inhaler devices was raised. The Committee considered the implications, but recognised that current nebulised treatments place a greater burden on people with physical disabilities than the use of an inhaler device.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No potential equality issues were raised in the submissions, expert statements or academic report.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No potential equality issues were identified by the Committee.
--

- | |
|--|
| 4. Do the preliminary recommendations make it more difficult in practice |
|--|

for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, as that the preliminary recommendations did not differentiate between any groups of people, the Committee concluded that its recommendations did not limit access to the technology for any specific group compared with other groups and that there was no need to alter or add to its recommendations.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, however the Committee did consider whether the inhaler used for mannitol inhalation would present a disproportionate burden on patients with physical disabilities, but the Committee noted the clinic and patient experts' view that current treatments would present more difficulties than mannitol.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, in section 4.35

Approved by Associate Director (name): Elisabeth George

Date: 24 05 12

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional potential equality issues were identified during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, the Committee concluded that its recommendations did not limit access to the technology for any specific group compared with other groups and that there was no need to alter or add to its recommendations.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, the Committee considered whether the inhaler used for mannitol inhalation would present a disproportionate burden on patients with physical disabilities. However, the Committee noted the clinical specialists' and patient expert's view that all available treatments are difficult to administer, and that the use mannitol as an add-on therapy to best standard of care would not increase the treatment burden.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, in section 4.30

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 09 10 12